Revolution Medicines, Inc. (RVMD)

業務介紹

革命醫藥公司是一家處於臨床階段的精準腫瘤學公司,專注於開發用於抑制RAS依賴型癌症前沿靶點的療法。該公司正在開發RMC-4630,這是一種SHP2抑制劑,正處於1/2期臨床試驗階段,用於治療實體瘤,如婦科和結直腸癌瘤。該公司還開發了RMC-5845,這是一種選擇性SOS1抑制劑,SOS1是一種將RAS(OFF)轉換為RAS(ON)的蛋白質;以及RMC-5552,這是一種腫瘤中mTORC1信號通路的高活性選擇性抑制劑。此外,該公司正在開發RMC-6291,這是一種選擇性抑制KRASG12C(ON)和NRASG12C(ON)的突變體抑制劑;以及RMC-6236,這是一種選擇性抑制多種RAS(ON)變體的RAS抑制劑。此外,它還開發了針對KRASG13C(ON)和KRASG12D(ON)的RAS(ON)抑制劑。該公司與賽諾菲有一項合作協議,用於研發SHP2抑制劑,包括RMC-4630。革命醫藥公司成立於2014年,總部位於加州雷德伍德城。



Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

公司網址

https://www.revmed.com